pyrazines has been researched along with mre 269 in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.45) | 29.6817 |
| 2010's | 26 (89.66) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Hashino, A; Kosugi, K; Kuwabara, K; Kuwano, K; Noda, K | 1 |
| Clozel, M; Ernst, R; Haag, F; Kauser, K; Morrison, K; Studer, R | 1 |
| Arnaud, C; Blaise, S; Boutonnat, J; Cracowski, JL; Godin-Ribuot, D; Kotzki, S; Roustit, M | 1 |
| Benyahia, C; Boukais, K; Clapp, L; Danel, C; Fabre, A; Gomez, I; Leséche, G; Longrois, D; Norel, X; Silverstein, A | 1 |
| Clapp, LH; Ledwozyw, A; Orie, NN; Whittle, BJ; Williams, DJ | 1 |
| Lang, IM; Skoro-Sajer, N | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Kaufmann, P | 1 |
| Bruderer, S; Dingemanse, J; Kaufmann, P; Mant, T; Mukai, H; Okubo, K; Yamada, T | 1 |
| Äänismaa, P; Bruderer, S; Dingemanse, J; Halabi, A; Kaufmann, P; Niglis, S; Segrestaa, J | 1 |
| Asaki, T; Clozel, M; Gatfield, J; Hamamoto, T; Kuwano, K; Morrison, K | 1 |
| Advani, A; Advani, SL; Azizi, PM; Batchu, SN; Bowskill, BB; Brijmohan, AS; Lee, WL; Liu, Y; Majumder, S; Thai, K; White, KE | 1 |
| Islam, MS; Jisaka, M; Khan, F; Nartey, MN; Nishimura, K; Rahman, MS; Shono, F; Syeda, PK; Yokota, K | 1 |
| Cruz, HG; Dingemanse, J; Halabi, A; Kaufmann, P; Krause, A; Ulč, I | 1 |
| Bruderer, S; Dingemanse, J; Mant, T; Mukai, H; Okubo, K | 1 |
| Astruc, B; Dingemanse, J; Hurst, N; Kaufmann, P | 1 |
| Fuchikami, C; Homan, J; Kosugi, K; Kuramoto, K; Kuwano, K; Murakami, K; Oka, M; Tajima, K | 1 |
| Clozel, M; Gatfield, J; Gnerre, C; Hess, P; Iglarz, M; Menyhart, K; Monnier, L; Morrison, K; Nayler, O; Wanner, D | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Remenova, T | 1 |
| Honorato Pérez, J | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Krause, A; Lott, D; Machacek, M | 1 |
| Alexander, JC; Candelario-Jalil, E; DeMars, KM; Febo, M; Yang, C | 1 |
| Boehler, M; Bruderer, S; Dingemanse, J; Ulč, I | 1 |
| Boehler, M; Bruderer, S; Dingemanse, J; Halabi, A; Petersen-Sylla, M; Remeňová, T | 1 |
| Äänismaa, P; de Kanter, R; Delahaye, S; Gnerre, C; Ichikawa, T; Pfeifer, T; Seeland, S; Segrestaa, J; Treiber, A; Yamada, T | 1 |
| Gnerre, C; Ichikawa, T; Nonaka, K; Seeland, S; Segrestaa, J; Treiber, A; Yamada, T | 1 |
| Brizzolara, R; Corallo, C; Cutolo, M; Giordano, N; Montagna, P; Paolino, S; Parodi, A; Pizzorni, C; Ruaro, B; Scabini, S; Smith, V; Soldano, S; Stratta, E; Sulli, A; Tavilla, PP; Trombetta, AC | 1 |
| Bauer, Y; Bolinger, M; Gatfield, J; Menyhart, K; Nayler, O; Renault, B; Schnoebelen, M; Studer, R; Zmajkovicova, K | 1 |
| Chen, J; Shi, L; Xie, S; Xu, RA; Ye, X | 1 |
| Chen, YA; Fan, C; Gu, EM; Luo, SB; Xu, RA; Zhou, SC | 1 |
3 review(s) available for pyrazines and mre 269
| Article | Year |
|---|---|
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines; Receptors, Prostaglandin; Signal Transduction | 2014 |
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Adult; Animals; Antihypertensive Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Topics: Acetamides; Acetates; Administration, Oral; Animals; Antihypertensive Agents; Drug Design; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2017 |
10 trial(s) available for pyrazines and mre 269
| Article | Year |
|---|---|
Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
Topics: Acetamides; Acetates; Administration, Oral; Adult; Double-Blind Method; Healthy Volunteers; Humans; Male; Maximum Tolerated Dose; Middle Aged; Platelet Aggregation; Pyrazines; Receptors, Epoprostenol | 2014 |
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Dose-Response Relationship, Drug; Double-Blind Method; Food-Drug Interactions; Half-Life; Humans; Male; Pyrazines; Receptors, Epoprostenol; Young Adult | 2015 |
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
Topics: Acetamides; Acetates; Adult; Antihypertensive Agents; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Healthy Volunteers; Humans; Lopinavir; Male; Middle Aged; Pyrazines; Ritonavir; Young Adult | 2015 |
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Topics: Acetamides; Acetates; Adult; Aged; Antihypertensive Agents; Area Under Curve; Case-Control Studies; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Prospective Studies; Pyrazines; Receptors, Epoprostenol; Severity of Illness Index | 2016 |
Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects.
Topics: Acetamides; Acetates; Adolescent; Adult; Anticoagulants; Cross-Over Studies; Double-Blind Method; Drug Interactions; Humans; International Normalized Ratio; Male; Middle Aged; Pyrazines; Warfarin; Young Adult | 2016 |
Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist.
Topics: Acetamides; Acetates; Administration, Oral; Adult; Antihypertensive Agents; Biological Availability; Cross-Over Studies; Humans; Infusions, Intravenous; Male; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Young Adult | 2017 |
Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
Topics: Acetamides; Acetates; Adult; Antihypertensive Agents; Bilirubin; Double-Blind Method; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Leukocyte Count; Male; Models, Biological; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazines; Treatment Outcome | 2017 |
Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.
Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Male; Middle Aged; Pyrazines; Therapeutic Equivalency; Young Adult | 2018 |
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Topics: Acetamides; Acetates; Activation, Metabolic; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Gemfibrozil; Germany; Half-Life; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Prodrugs; Pyrazines; Rifampin; Risk Assessment; Young Adult | 2017 |
The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.
Topics: Acetamides; Acetates; Drug Interactions; Enzyme Inhibitors; Esterases; Hepatocytes; Humans; Membrane Transport Proteins; Metabolic Networks and Pathways; Metabolome; Metabolomics; Microsomes, Liver; NADP; Pyrazines; Receptors, Epoprostenol; Recombinant Proteins; RNA, Messenger | 2018 |
16 other study(ies) available for pyrazines and mre 269
| Article | Year |
|---|---|
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active fo
Topics: Acetamides; Acetates; Animals; Antihypertensive Agents; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; In Vitro Techniques; Male; Prodrugs; Pulmonary Artery; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation | 2008 |
Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Topics: Acetamides; Acetates; Alprostadil; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Epoprostenol; Hypertension, Pulmonary; In Vitro Techniques; Male; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Receptors, Epoprostenol; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2012 |
Anodal iontophoresis of a soluble guanylate cyclase stimulator induces a sustained increase in skin blood flow in rats.
Topics: Acetates; Acrylamides; Animals; Data Interpretation, Statistical; Electric Stimulation; Electrodes; Guanylate Cyclase; In Vitro Techniques; Iontophoresis; Male; Nitrosamines; Oxazoles; Platelet Aggregation Inhibitors; Pyrazines; Pyrazoles; Rats; Rats, Wistar; Receptors, Epoprostenol; Regional Blood Flow; Skin | 2013 |
A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
Topics: Acetates; Aged; Drug Evaluation, Preclinical; Epoprostenol; Female; Humans; Iloprost; In Vitro Techniques; Inhibitory Concentration 50; Male; Middle Aged; Molecular Mimicry; Pulmonary Artery; Pulmonary Veins; Pyrazines; Receptors, Epoprostenol; Receptors, Immunologic; Receptors, Prostaglandin; Receptors, Prostaglandin E, EP4 Subtype; Vasodilation; Vasodilator Agents | 2013 |
Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Topics: Acetamides; Acetates; Animals; Benzofurans; Benzyl Compounds; Epoprostenol; Female; Iloprost; Imidazoles; Male; Propionates; Pulmonary Artery; Pulmonary Veins; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation | 2013 |
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Animals; CHO Cells; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cricetulus; Dogs; Double-Blind Method; Haplorhini; Humans; Hypertension, Pulmonary; Myocytes, Smooth Muscle; Platelet Aggregation Inhibitors; Pulmonary Artery; Pyrazines; Randomized Controlled Trials as Topic; Rats; Receptors, Epoprostenol; Structure-Activity Relationship | 2015 |
Prostaglandin I2 Receptor Agonism Preserves β-Cell Function and Attenuates Albuminuria Through Nephrin-Dependent Mechanisms.
Topics: Acetamides; Acetates; Animals; Cell Line; Cell Survival; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Membrane Proteins; Mice, Inbred C57BL; Mice, Knockout; Mutation; Phosphorylation; Podocytes; Prodrugs; Protein Processing, Post-Translational; Pyrazines; Receptors, Epoprostenol; Renal Insufficiency; RNA Interference | 2016 |
Pretreatment of cultured preadipocytes with arachidonic acid during the differentiation phase without a cAMP-elevating agent enhances fat storage after the maturation phase.
Topics: 1-Methyl-3-isobutylxanthine; 3T3-L1 Cells; 6-Ketoprostaglandin F1 alpha; Acetates; Adipocytes; Adipogenesis; Animals; Arachidonic Acid; Cell Differentiation; Cells, Cultured; Cyclic AMP; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprost; Dinoprostone; Gene Expression Regulation; Humans; Hydroxyprostaglandin Dehydrogenases; Membrane Proteins; Mesenchymal Stem Cells; Mice; Prostaglandin-E Synthases; Pyrazines; Receptors, Prostaglandin; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; Triglycerides | 2016 |
A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonar
Topics: Acetamides; Acetates; Animals; Cyclic AMP; Endothelium, Vascular; Humans; Male; Nitric Oxide; Pulmonary Artery; Pyrazines; Rats; Receptors, Epoprostenol; Swine; Vasodilation; Vasodilator Agents | 2017 |
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Topics: Acetamides; Acetates; Animals; beta-Arrestins; Cell Proliferation; CHO Cells; Contractile Proteins; Cricetinae; Cricetulus; Cyclic AMP; Epoprostenol; Extracellular Matrix; Humans; Hypertension, Pulmonary; Iloprost; Male; Muscle Contraction; Muscle Relaxation; Pyrazines; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Epoprostenol | 2017 |
Sustained Neurological Recovery After Stroke in Aged Rats Treated With a Novel Prostacyclin Analog.
Topics: Acetates; Age Factors; Animals; Brain Ischemia; Epoprostenol; Infarction, Middle Cerebral Artery; Male; Pyrazines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Prostaglandin; Stroke | 2017 |
Cross-species comparison of the metabolism and excretion of selexipag.
Topics: Acetamides; Acetates; Animals; Bile; Body Fluids; Chromatography, High Pressure Liquid; Dogs; Hepatocytes; Macaca fascicularis; Metabolome; Microsomes, Liver; Pyrazines; Rats; Rats, Sprague-Dawley; Species Specificity | 2019 |
Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.
Topics: Acetamides; Acetates; Actins; Aged; Cells, Cultured; Female; Fibroblasts; Gene Expression; Humans; Middle Aged; Muscle, Smooth; Myofibroblasts; Pyrazines; S100 Calcium-Binding Protein A4; Scleroderma, Systemic; Skin | 2018 |
The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ.
Topics: Acetates; Acyltransferases; Adaptor Proteins, Signal Transducing; Case-Control Studies; Cell Differentiation; Cell Proliferation; Cyclic AMP; Extracellular Matrix; Fibroblasts; Gene Expression Regulation; Humans; Idiopathic Pulmonary Fibrosis; Interleukin-6; Lung; Male; Myofibroblasts; Plasminogen Activator Inhibitor 1; Pyrazines; Receptors, Epoprostenol; Signal Transduction; Transcription Factors; Transcription, Genetic; Transforming Growth Factor beta1; YAP-Signaling Proteins | 2019 |
Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method.
Topics: Acetamides; Acetates; Animals; Chromatography, High Pressure Liquid; Chromatography, Liquid; Pyrazines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2020 |
Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles.
Topics: Acetamides; Acetates; Animals; Antihypertensive Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C8 Inhibitors; Dogs; Female; Herb-Drug Interactions; Male; Pyrazines; Quercetin; Tandem Mass Spectrometry | 2022 |